E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL)

Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10.1200/JCO.2012.43.4803

Untreated Stage III/IV, or Locally Extensive (>1/3

mediastinum) HL

n=854

ABVD x 6-8 + IFRT (36 Gy) to bulky mediastinal lesions

n=428

Stratification0-2 vs 3-7 adverse factors*

Locally extensive vs Stage III/IV

Stanford V + IFRT (36 Gy) to lesions >5 cm

n=426

R

ABVD Dosage

Doxorrubicin 25 mg/m2 IV días 1 y 15

Bleomycin 10 u/m2 IV días 1 y 15

Vinblastine 6 mg/m2 IV días 1 y 15

Dacarbazine 375 mg/m2 IV días 1 y 15

Stanford V Dosage

Doxorrubicin 25 mg/m2 IV weeks 1, 3, 5, 7, 9 and 11

Vinblastine 6 mg/m2 IV weeks 1, 3, 5, 7, 9 and 11

Nitrogen mustard 6 mg/m2 IV weeks 1, 5, and 9

Etoposide 60 mg/m2 x2 V weeks 3, 7, and 11

Vincristine 1.4 mg/m2 IV weeks 2, 4, 6, 8, 10 and 12

Bleomycin 5 u/m2 IV weeks 2, 4, 6, 8, 10 and 12

Prednisone 40 mg q other day x 12 weeks (Taper week 10-12)

Creada por: Mauricio Lema Medina MD 1/2

OutcomesFailure-Free Survival

(FFS)**

Overall Survival (OS)

FFS: Time from randomization to progression, relapse or death, whichever occurred first

E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL)

Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10.1200/JCO.2012.43.4803 Creada por: Mauricio Lema Medina MD 2/2

%

ABVD remains the standard of care for patients with advanced Hodgkin lymphoma.

Treatment of Advanced Hodgkin Lymphoma: The More Things Change,

the More They Stay the Same

Longo DL. J Clin Oncol DOI:10.1200/JCO.2012.44.7235